Hims & Hers Health (NYSE:HIMS) Given Neutral Rating at Piper Sandler

Hims & Hers Health (NYSE:HIMS)‘s stock had its “neutral” rating reaffirmed by Piper Sandler in a research report issued on Tuesday, Benzinga reports. They currently have a $18.00 price target on the stock. Piper Sandler’s price target suggests a potential upside of 2.68% from the company’s current price.

A number of other analysts also recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Canaccord Genuity Group began coverage on Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target for the company. Jefferies Financial Group lifted their price target on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, June 27th. Seaport Res Ptn reiterated a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Finally, Citigroup downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their price target for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Seven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Moderate Buy” and a consensus price target of $19.07.

Hims & Hers Health Price Performance

HIMS stock traded down $0.31 during mid-day trading on Tuesday, reaching $17.53. 14,666,048 shares of the company traded hands, compared to its average volume of 7,754,355. The company has a market capitalization of $3.77 billion, a P/E ratio of -1,752.00 and a beta of 1.08. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $25.74. The company has a fifty day moving average price of $21.39 and a 200-day moving average price of $15.80.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company’s quarterly revenue was up 51.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.03) EPS. As a group, analysts forecast that Hims & Hers Health will post 0.2 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total value of $45,188.00. Following the completion of the sale, the insider now owns 185,326 shares in the company, valued at $4,077,172. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $19.88, for a total transaction of $3,755,093.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $22.00, for a total value of $45,188.00. Following the transaction, the insider now directly owns 185,326 shares in the company, valued at $4,077,172. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 782,901 shares of company stock worth $16,138,997. 17.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the business. Forerunner Ventures Management LLC purchased a new stake in Hims & Hers Health in the fourth quarter worth $86,836,000. Farallon Capital Management LLC grew its stake in shares of Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares during the last quarter. M&G Plc purchased a new stake in shares of Hims & Hers Health in the first quarter worth $8,232,000. State of Michigan Retirement System grew its stake in shares of Hims & Hers Health by 177.8% in the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after acquiring an additional 320,000 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Hims & Hers Health by 67.5% in the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after acquiring an additional 273,473 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.